Scientific Publications

The landmark research of BostonGene underscores the importance of combining innovative multi-platform analytics with cutting-edge software to improve patient outcomes. Explore our scientific publications to learn more.

Molecular-based tumor grade predictor for breast cancer, clear cell renal cell carcinoma, and lung adenocarcinoma
Cancer Research, 2022
Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression
Blood Cancer Discovery, 2022
A digital imaging analysis (DIA) platform for identifying tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD).
Journal of Clinical Oncology, 2022
A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.
Journal of Clinical Oncology, 2022
A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response.
Journal of Clinical Oncology, 2022
Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer
Journal of Clinical Oncology, 2022
Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma
Clinical Cancer Research, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine, 2021
The Combination of Duvelisib and Romidepsin (DR) Is Highly Active Against Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Final Results and Biomarker Analysis
Blood Journals, 2021
High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study
Blood Journals, 2021
Contact us